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PCASE7
INCLUDING A PHARMACOECONOMIC MODEL IN THE
FORMULARY REVIEW PROCESS OF NEW
Grossomanides J1, Possidente C2
1Blue Cross Blue Shield of Vermont, Berlin,VT, USA, 2Pﬁzer, Jericho
Center,VT, USA
Organization: Blue Cross Blue Shield of Vermont
Problem or Issue Addressed: Approval of new prescription prod-
ucts by the Federal Drug Administration dictates that organiza-
tions review the medication and consider the drug’s position on
the formulary. Pharmacy and Therapeutics Committee members
are required to consider many factor.
Goals: Utilize a pharmacoeconomic model to evaluate the impact
of pregabalin per member per month (PMPM) costs and incor-
porate this information into the formulary review process to
determine the appropriate formulary status of pregabalin.
Outcomes items used in the decision: Per member per month
(PMPM) costs, and the organization’s drug costs and utilization
patterns of selected agents for epilepsy and neuropathic pain
were reviewed.
Implementation Strategy: Drug utilization data for all second
generation antiepileptic drugs and medications commonly used
to treat neuropathic pain were reviewed. The drug costs per day
and the number patients prescribed each drug were collected
monthly. Total drug costs and PMPM costs were calculated for
each month between September 2005 and November 2006 using
Therapy Cost GPS. Therapy Cost GPS is an analytical software
tool, developed by Pﬁzer, Inc. that supports the development of
cost models to assess the ﬁnancial impact of formulary changes
before they are established and accurately evaluates their impact
once they have been implemented. The results were compared to
the same parameters from August 2005, which served as a base-
line before pregabalin was available. The available results were
included with the pregabalin formulary presentation to the Phar-
macy and Therapeutics Committee in April 2006, with the com-
mitment for continual evaluation.
Results: A total of 6259 patients received drugs targeted for
analysis in August 2005, accounting for $1,829,626 in total drug
costs, and a PMPM cost of $1.02. In November 2006 after 15
months, 5825 patients received drugs targeted for analysis, and
total drug costs decreased by 7.2% to $1,698,187. The PMPM
cost was reduced to $0.94, a reduction independent of patient
number. During November 2006 pregabalin prescribing was
limited, accounting for approximately 2% utilization of com-
parator drugs. Mean (+/− SD) monthly values during the 15-
month data collection period for number patients, total drug
costs and PMPM cost were; 5761 (326), $1,726,090 ($42,008),
$0.96 ($0.02), respectively. The data suggests pregabalin usage
and PMPM costs are projected to remain stable. Shifting drug
utilization patterns and reductions in the cost of generic
gabapentin likely accounted for the reduced PMPM cost.
Because pregabalin utilization was limited and did not increase
the PMPM costs, it was decided to continue the drug’s position
as an unrestricted third tier agent, without the need to imple-
ment a step edit or prior authorization requirement.
Lessons Learned: Because utilization of pregabalin during the
ﬁrst year has been limited, it is unclear if the ﬁnancial implica-
tions will change over time. Ongoing evaluation will be con-
ducted to further assess pregabalin utilization patterns and
determine if increased utilization is observed and if formulary
adjustments are required. Patient diagnosis was not available so
the indication for pregabalin was not included in the review.
Other organizations with access to linked pharmacy and medical
databases could reﬁne the review process by focusing on drug
therapy for a speciﬁc indication. The monthly monitoring of
drug utilization patterns and costs provides helpful information
to evaluate the formulary position of newly available drugs, and
allows a concurrent review of existing therapies. Changes in
generic drug usage, cost reductions associated with shifts from
single source to multi-source generic products, and increased
costs of branded products are examples of changes readily
observed with an ongoing review process. As a result of this
project, cost models will be integrated into the formulary review
process as additional new drugs become available. In addition,
future plans include using a similar cost model to evaluate estab-
lished drugs and drug class reviews.
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POLYPHARMACY MEDICATION THERAPY MANAGEMENT
PROGRAM (MTMP) CASE STUDY
Miller SA, Mu Y, Lou Y, Huang Z, Radzicki R, Cozzi G, Heath P,
Sekula R, Lee KK
Walgreens Health Services, Deerﬁeld, IL, USA
Organization: Walgreens Health Services
Problem or Issue Addressed: Approximately one-third of the
elderly population is at risk for polypharmacy and its complica-
tion. Polypharmacy increases patients’ risks for many ill effects,
including drug interactions, non-adherence, hospitalizations,
morbidity and mortality.
Goals: The WHS Polypharmacy MTMP is designed to ensure
optimum therapeutic, clinical and ﬁnancial outcomes by pro-
moting proper prescribing and improving patient medication
use. Three polypharmacy cases were examined to illustrate the
process of polypharmacy intervention process and how such
interventions may help reduce health care expenditures.
Outcomes items used in the decision: a) Drug therapy outcomes:
reduction in drug interactions and therapeutic duplications,
ensuring appropriateness of medication therapies and improved
compliance and persistency; b) Literature-based clinical out-
comes: reduction in the incidence and severity of adverse events
including falls and fractures, hospitalizations, nursing home
admissions, morbidity and mortality; c) Financial outcomes:
pharmacy and medical cost savings.
Implementation Strategy: 1) Identify polypharmacy MTMP can-
didates based on number of disease states, number of mainte-
nance medications and estimated yearly drug spend; 2) Enroll
polypharmacy MTMP candidates according to program speciﬁ-
cation (Opt-in or Opt-out model). 3) Review member medica-
tion proﬁles by pharmacists at the MTM clinical call center,
utilizing a Medication Appropriateness Index. 4) Contact the
prescribing physician to discuss the identiﬁed medication-related
issues and recommend possible therapeutic solutions. 5) Docu-
ment the results of the clinical intervention and fax/mail a copy
of the Medication Action Plan (MAP), Personal Medication
Record (PMR) and dosing calendar to the participant’s commu-
nity pharmacist and/or patient; 6) Counsel patient on therapy
changes and proper medication use. 7) Follow up on polyphar-
macy intervention outcomes.
Results: Case One: Ten medications were intervened upon by
MTM call center pharmacists after a patient’s medication history
was reviewed. Speciﬁc interventions accepted by the prescriber
included: combining multiple medications to a single medication
for the purpose of decreasing pill load; generic substitution to
reduce cost; reducing dosage to help ensure safe dosage in the
elderly; discontinuing duplicated medication. Assuming all med-
ications were maintenance medications and the patient would be
in full compliance with the recommended medications for the
next 12 months, the total pharmacy saving for this case would
be $4,413 per year.
